(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/159205 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/062845

(22) International Filing Date:
10 December 2021 (10.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/123,529 10 December 2020 (10.12.2020) US

(71) Applicant: **AMNEAL COMPLEX PRODUCTS RESEARCH LLC** [US/—]; 995 Us Highway 202/206, Bridgewater, NJ 08807 (US).

(72) Inventors: **VAKA, Siva, Ram Kiran**; 404a Carlton Avenue, Piscataway, NJ 08854 (US). **DESAL, Dipen**; 202 Altaview Court, Whippany, NJ 07981 (US). **SHAH, Navnit, H.**; 115 Bernini Way, Monmouth Junction, NJ 08852 (US). **PHUAPRADIT, Wantanee**; 24950 Lenape Road, Lewes, DE 19958 (US). **SHELKE, Namdev, B.**; 574 Auten Road, 6h, Hillsborough, NJ 08844 (US).

(74) Agent: **AWASTHI, Vandana**; 995 US Highway 202/206, Bridgewater, NJ 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE




FIGURE 3B

(57) Abstract: The present disclosure provides extended release pyridostigmine compositions for symptomatic treatment of myasthenia gravis; pretreatment for exposure to the chemical nerve agent Soman; and/or the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure),. The compositions of the disclosure provide reduced Fluctuation Index; reduced/blunted Cmax; higher Cmin, reduced Cmax: Cmin ratio, and reduced initial burst release of the drug, as compared to marketed pyridostigmine products. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs.

WO 2022/159205 A2

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*